Altered intercellular communication — how the body's cells stop talking clearly

To understand why that old experiment matters, you have to start with a fact that is easy to state and hard to fully absorb: a human body is not really a single thing. It is a society of roughly thirty trillion cells, and like any society it functions only because its members communicate. No cell acts alone. Every heartbeat, every immune response, every wound that closes and every meal that gets metabolized depends on cells sending and receiving messages, coordinating their behavior across distances that, from a cell's point of view, are vast. When that communication is clear, the body behaves as an organism. When it drifts and degrades, the body behaves more like a crowd that has stopped listening to one another — and that degradation is now formally recognized as one of the hallmarks of aging, listed under the name altered intercellular communication.

Cells talk through several distinct channels, and it helps to know them, because aging affects each. The most intimate is direct contact: cells physically touch, and proteins on their surfaces read one another like a handshake, conveying identity and instruction. Closely related are gap junctions — tiny protein channels that connect the interiors of adjacent cells directly, letting small molecules and ions flow between them so that, for example, heart muscle cells can fire in unison and a wave of coordinated contraction can sweep across the heart. A step outward is paracrine signaling, in which a cell releases a molecule that diffuses a short distance to affect its neighbors — the local conversation of a tissue, governing inflammation, growth, and repair. Further out still is endocrine signaling: hormones released into the blood that travel the whole body to reach distant targets, the long-range broadcast system that coordinates metabolism, stress, reproduction, and growth across organs.

And then there is the channel that has reorganized the whole field in the last twenty years: extracellular vesicles, of which exosomes are the most discussed. An exosome is a tiny bubble of membrane, far smaller than a cell, that a cell pinches off and releases into the surrounding fluid or the bloodstream. Inside and on the surface it carries cargo — proteins, lipids, and crucially RNA molecules, including the regulatory microRNAs that tune which genes a recipient cell expresses. When another cell takes up that vesicle, it receives a package of molecular instructions assembled by the sender. This is not a vague chemical signal but something closer to a parcel with contents. The discovery that cells routinely ship such parcels to one another, across short and long distances, transformed how biologists picture intercellular communication. The body is not just shouting hormones and whispering to neighbors; it is mailing detailed instructions, constantly, in their billions.

What goes wrong with all of this in aging is best captured by a single coined word: inflammaging. The Italian immunologist Claudio Franceschi proposed the term to describe a chronic, low-grade, smoldering inflammation that develops with age in the absence of any acute infection — a sterile inflammation, with no enemy to fight, that simply rises as a background tone. Inflammaging is not the dramatic, useful inflammation of a cut or a flu. It is a persistent, slightly elevated hum of inflammatory signaling that the body cannot seem to switch off, and it is now linked to a remarkable range of age-related conditions: atherosclerosis, type 2 diabetes, neurodegeneration, frailty, and more. The signaling environment of an old body is, quite literally, inflamed relative to a young one, and that altered chemical climate changes how every cell behaves.

A major source of inflammaging is the senescent cell, and the connection ties this hallmark to another. Senescent cells are cells that have permanently stopped dividing — often in response to damage or stress — but have not died and been cleared. They linger in tissues, and as they linger they secrete a characteristic cocktail of inflammatory cytokines, growth factors, and enzymes known as the senescence-associated secretory phenotype, or SASP. A senescent cell, in other words, is not a quiet retiree; it is a loud broadcaster of pro-inflammatory and tissue-degrading signals. As senescent cells accumulate with age — partly because the immune system that should clear them becomes less efficient — their collective SASP raises the inflammatory tone of the whole body and actively pushes neighboring healthy cells toward dysfunction and senescence themselves. It is a self-amplifying corruption of the local signaling environment, and it is the leading mechanistic explanation for why inflammaging worsens over time.

The exosome story changes with age too. The cargo cells package shifts: the proteins and microRNAs carried in older vesicles differ from those in young ones, and some of these altered parcels appear to transmit aging-associated signals rather than regenerative ones. A vesicle is only as helpful as its contents, and an old body's vesicles seem, on balance, to carry more of the wrong instructions. Hormonal signaling declines along well-known axes — growth hormone and its downstream factor IGF-1, the sex hormones, and others fall or become dysregulated — and gap junction communication can degrade in tissues like the aging heart, contributing to arrhythmias. The overall picture is not the failure of one channel but a coordinated blurring across all of them: the society of cells loses fidelity in how it talks to itself.

This is where McCay's macabre experiment returns, modernized. In the 2000s, laboratories led by researchers including Thomas Rando, Amy Wagers, Tony Wyss-Coray, and Saul Villeda revived parabiosis with far better controls and far sharper questions. Joining the circulation of an old mouse to a young one — heterochronic parabiosis — produced striking results. Old muscle regenerated better. Old livers showed improved function. In the brain, the hippocampus of old mice showed increased neural stem cell activity and improvements in measures of learning and memory. Critically, the experiments pointed away from the romantic idea that young cells were doing the work. Filtered young plasma — blood with the cells removed — could reproduce some of the benefits, which meant the active agents were soluble circulating factors: proteins, vesicles, and signaling molecules, not whole cells migrating from young to old. The blood was carrying instructions, and young blood carried instructions that partially restored youthful behavior in old tissue.

The follow-up question split the field into two camps that are still debating. One view holds that young blood supplies beneficial pro-youthful factors that old bodies lack. The other holds that the dominant effect is dilution — that joining to a young circulation dilutes the pro-aging factors that accumulate in old blood, and that simply lowering those harmful signals does much of the work. Evidence exists for both. Some specific youthful factors have been proposed and studied, though several early candidates proved contentious and harder to replicate than the headlines suggested. Meanwhile, experiments showing that simply diluting old plasma with a neutral solution produced benefits gave real weight to the dilution hypothesis. The honest current position is that both mechanisms likely contribute, and that the simplistic story of a single magic rejuvenation molecule in young blood has not held up.

These findings drove two human-facing research directions, and both deserve a clear-eyed description. The first is young-plasma infusion, which became briefly notorious when commercial ventures began selling transfusions of young donor plasma as anti-aging treatment. The FDA issued a pointed warning in 2019 against such offerings, noting they had no proven benefit and carried real transfusion risks. The science did not support the commerce. The second, more rigorous direction is therapeutic plasma exchange — a long-established medical procedure in which a patient's plasma is removed and replaced, used legitimately for certain autoimmune and neurological conditions. Researchers have begun studying whether plasma exchange might lower the burden of pro-aging circulating factors, drawing directly on the dilution hypothesis. This work is early. It is being done as research, not as approved anti-aging therapy, and no one should mistake a controlled trial for an available treatment.

The exosome-therapeutics field grows from the same root. If exosomes carry the molecular instructions that aging degrades, then exosomes from young, healthy, or stem-cell sources might be used to deliver corrective signals — and, separately, exosomes are attractive as engineered delivery vehicles for drugs and RNA because the body already uses them for exactly that purpose. The legitimate research here is substantial and serious. But the commercial reality has run far ahead of the evidence: clinics and product lines market exosome injections and topicals for skin rejuvenation, hair restoration, joint repair, and general anti-aging, and these products are not FDA-approved. The FDA has issued explicit safety warnings about unapproved exosome products, including reports of serious adverse events. The mechanism is genuinely promising; the marketplace is genuinely unregulated, and the distinction matters enormously for anyone considering it.

Peptides intersect this hallmark precisely because peptides are, themselves, intercellular signaling molecules — short chains of amino acids that the body uses as messengers. Many of the hormones and paracrine signals described above are peptides. In a research context, the interest is in whether specific synthetic peptides can influence the signaling environment: modulating inflammatory cytokine production, supporting tissue repair signaling, or affecting the pathways that govern senescence and the SASP. Thymosin beta-4 and its fragment TB-500 are studied in animal models for cell migration and repair signaling; BPC-157 is studied preclinically for effects on growth-factor pathways and angiogenesis; thymic peptides are researched for immune signaling. The framing has to stay disciplined. These are studied for their effects on signaling pathways, largely in preclinical and animal research; none is an approved anti-inflammaging therapy, and the human evidence is limited. The conceptual link — that the language of cells is partly written in peptides — is real and is exactly why the category attracts research attention, but a coherent mechanism is not the same thing as a proven treatment, and the difference belongs in any conversation with a prescribing provider.

Step back and the through-line is clear. The diseases and declines of aging are not only the failures of individual cells wearing out. They are, to a degree biologists are still mapping, failures of coordination — a society of cells whose messages have grown noisier, more inflammatory, and less trustworthy, so that even structurally intact cells receive corrupted instructions and behave accordingly. That is a hopeful framing in one respect, because a communication problem is, in principle, a more tractable target than the wholesale replacement of worn parts. If the signals can be cleaned up — the inflammatory tone lowered, the senescent broadcasters cleared, the right cargo restored — the existing cells might simply behave younger. That is the bet the whole field is making, and the most honest thing to say about it is that the biology is real, the early experiments are tantalizing, and the marketplace selling its promise has, so far, outrun the proof.